medigraphic.com
ISSN 2448-5640 (Print)
Diario Oficial de la Sociedad Mexicana de Cirugía Cardiaca, A.C., y del Colegio Mexicano de Cirugía Cardiovascular y Torácica, A.C.

2023, Number 2

Next >>

Cir Card Mex 2023; 8 (2)

COAPT trial in the current era. Apertis verbis still much to be clarified

García-Villarreal OA

Language: English
References: 29
Page: 25-28
PDF size: 148.44 Kb.


Text Extraction

There has been an ever-increasing interest in catheter- based techniques to treat structural heart diseases. The question of using transcatheter edge-to-edge repair (TEER) more efficiently in order to treat the severe functional mitral regurgitation (FMR) has been basically the main objective throughout the last years. Accessing novel cutting-edge technological breakthroughs may offer great promises of treatment options, but without recognizing the limitations of the TEER technique, its usage may never become a permanent part of our daily practice routine. Thus, the essential problem concerns how to implement more efficient practices such that they will be integrated in and complement other aspects of the current armamentarium at hand to treat mitral regurgitation (MR).


REFERENCES

  1. Giustino G, Camaj A, Kapadia S, et al. Hospitalizations and Mortality in Patientswith Secondary Mitral Regurgitation and Heart Failure: The COAPT Trial. J AmColl Cardiol. 2022, 80 (20) 1857–1868. doi: 10.1016/j.jacc.2022.08.803

  2. Stone GW, Lindenfeld J, Abraham WT, et al; COAPT Investigators. TranscatheterMitral-Valve Repair in Patients with Heart Failure. N Engl J Med.2018;379(24):2307-2318. doi: 10.1056/NEJMoa1806640.

  3. García-Villarreal OA. Chasm between the Guided-Directed Medical Therapy forfunctional mitral regurgitation used in the COAPT trial and present time: a majorrevision is mandatory. Cir Card Mex 2022; 7(4): 61-64.

  4. Iung B, Armoiry X, Vahanian A, et al; MITRA-FR Investigators. Percutaneous repairor medical treatment for secondary mitral regurgitation: outcomes at 2 years.Eur J Heart Fail. 2019;21(12):1619-1627. doi: 10.1002/ejhf.1616.

  5. García-Villarreal OA. Transcatheter Edge-to-Edge Mitral Valve Repair in FunctionalMitral Regurgitation. Does it Pass Muster? Still Leaving Plenty to Be Desired.Braz J Cardiovasc Surg. 2022;37(2):I-IV. doi: 10.21470/1678-9741-2022-0129.

  6. García-Villarreal OA. Transcatheter edge-to-edge valve repair in functional mitralregurgitation. Eur J Cardiothorac Surg. 2022;62(2):ezab521. doi: 10.1093/ejcts/ezab521.

  7. Grayburn PA, Sannino A, Packer M. Proportionate and Disproportionate FunctionalMitral Regurgitation: A New Conceptual Framework That Reconciles theResults of the MITRA-FR and COAPT Trials. JACC Cardiovasc Imaging. 2019Feb;12(2):353-362. doi: 10.1016/j.jcmg.2018.11.006.

  8. Hagendorff A, Knebel F, Helfen A, Stöbe S, Doenst T, Falk V. Disproportionatemitral regurgitation: another myth? A critical appraisal of echocardiographicassessment of functional mitral regurgitation. Int J Cardiovasc Imaging. 2021Jan;37(1):183-196. doi: 10.1007/s10554-020-01975-6.

  9. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for theManagement of Patients with Valvular Heart Disease: Executive Summary:A Report of the American College of Cardiology/American Heart AssociationJoint Committee on Clinical Practice Guidelines. Circulation. 2021 Feb2;143(5):e35-e71. doi: 10.1161/CIR.0000000000000932.

  10. Vahanian A, Beyersdorf F, Praz F, et al; ESC/EACTS Scientific Document Group.2021 ESC/EACTS Guidelines for the management of valvular heart disease. EurJ Cardiothorac Surg. 2021 Oct 22;60(4):727-800. doi: 10.1093/ejcts/ezab389.

  11. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trendsin preva-lence and outcome of heart failure with preserved ejection fraction. NEngl J Med. 2006;355(3):251-9. doi: 10.1056/NEJMoa052256.

  12. Varadarajan P, Sharma S, Heywood JT, Pai RG. High prevalence of clinicallysilent severe mitral regurgitation in patients with heart failure: role for echocardiography.J Am Soc Echocardiogr. 2006;19(12):1458-61. doi: 10.1016/j.echo.2006.06.009.

  13. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline forthe Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Circulation. 2022;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063.

  14. Nasser R, Van Assche L, Vorlat A, et al. Evolution of Functional Mitral Regurgitationand Prognosis in Medically Managed Heart Failure Patients with ReducedEjection Fraction. JACC Heart Fail. 2017;5(9):652-659. doi: 10.1016/j.jchf.2017.06.015.

  15. Januzzi JL, Omar AMS, Liu Y, et al. Association Between Sacubitril/ValsartanInitiation and Mitral Regurgitation Severity in Heart Failure with Reduced EjectionFraction: The PROVE-HF Study. Circulation. 2022;146(21):1638-1640. doi:10.1161/CIRCULATIONAHA.122.061693.

  16. Ezekowitz JA. Residuals: Mitral Regurgitation, Bias, and Effects of MedicalTherapy. Circulation. 2021;144(6):438-440. doi:10.1161/CIRCULATIONAHA.121.055707.

  17. DeFilippis EM, Fiuzat M. Putting the "Optimal" in Optimal Medical Therapy.JACC Heart Fail. 2021;9(1):39-41. doi: 10.1016/j.jchf.2020.08.016.

  18. Greene SJ, Butler J, Albert NM, et al. Medical Therapy for Heart Failure withReduced Ejection Fraction: The CHAMP-HF Registry. J Am Coll Cardiol. 2018Jul 24;72(4):351-366. doi: 10.1016/j.jacc.2018.04.070.

  19. Greene SJ, Fonarow GC, DeVore AD, et al. Titration of Medical Therapy for HeartFailure with Reduced Ejection Fraction. J Am Coll Cardiol. 2019;73(19):2365-2383. doi: 10.1016/j.jacc.2019.02.015.

  20. Fiuzat M, Ezekowitz J, Alemayehu W, et al. Assessment of Limitations to Optimizationof Guideline-Directed Medical Therapy in Heart Failure From the GUIDEITTrial: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol.2020;5(7):757-764. doi: 10.1001/jamacardio.2020.0640.

  21. Supplementary Appendix to: Stone GW, Lindenfeld JA, Abraham WT, et al.Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med2018;379:2307-18. DOI: 10.1056/NEJMoa1806640.

  22. Lindfield J, et al. J Am Coll Cardiol. 2020, 75 (11_Supplement_1) 973 (Abstract2020).

  23. Cox ZL, et al. Maximally-tolerated guideline-directed medical therapy and barriersto optimizationi in patients with HF with HFrEF: The COAPT trial. (2022,Abstract ESC 2022).

  24. Buzzatti N, De Bonis M, Denti P, et al. What is a "good" result after transcathetermitral repair? Impact of 2+ residual mitral regurgitation. J Thorac CardiovascSurg. 2016;151(1):88-96. doi: 10.1016/j.jtcvs.2015.09.099.

  25. Reichart D, Kalbacher D, Rübsamen N, et al. The impact of residual mitral regurgitationafter MitraClip therapy in functional mitral regurgitation. Eur J Heart Fail.2020;22(10):1840-1848. doi: 10.1002/ejhf.1774.

  26. Sugiura A, Kavsur R, Spieker M, Iliadis C, Goto T, Öztürk C, Weber M, Tabata N,Zimmer S, Sinning JM, Mauri V, et al. Recurrent Mitral Regurgitation After Mitra-Clip: Predictive Factors, Morphology, and Clinical Implication. Circ CardiovascInterv. 2022;15(3):e010895. doi: 10.1161/CIRCINTERVENTIONS.121.010895.

  27. Arnold SV, Chinnakondepalli KM, Spertus JA,; COAPT Investigators. HealthStatus After Transcatheter Mitral-Valve Repair in Heart Failure and SecondaryMitral Regurgitation: COAPT Trial. J Am Coll Cardiol. 2019;73(17):2123-2132.doi: 10.1016/j.jacc.2019.02.010.

  28. van Wijngaarden SE, Kamperidis V, Al-Amri I, et al. Effects of TranscatheterMitral Valve Repair with MitraClip on Left Ventricular and Atrial HemodynamicLoad and Myocardial Wall Stress. J Card Fail. 2018;24(3):137-145. doi:10.1016/j.cardfail.2017.12.008.

  29. Fine NM, McAlister FA, Howlett JG, Youngson E, Ezekowitz JA. Low Prevalenceof Transcatheter Mitral Valve Repair Eligibility in a Community Heart FailurePopulation. Circ Heart Fail. 2020;13(5):e006952. doi: 10.1161/CIRCHEARTFAILURE.120.006952.




2020     |     www.medigraphic.com